$OTLK
Outlook Therapeutics, Inc.

2022 Q1 Form 10-Q Financial Statement

#000155837022008780 Filed on May 13, 2022

View on sec.gov

Income Statement

Concept 2022 Q1 2021 Q1
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $6.690M $4.100M
YoY Change 63.17% 109.18%
% of Gross Profit
Research & Development $12.22M $8.529M
YoY Change 43.27% 94.74%
% of Gross Profit
Depreciation & Amortization $40.91K $40.91K
YoY Change 0.0% -75.94%
% of Gross Profit
Operating Expenses $12.22M $8.529M
YoY Change 43.27% 34.53%
Operating Profit -$18.91M -$12.63M
YoY Change 49.78%
Interest Expense -$424.4K -$250.0K
YoY Change 69.75% -64.29%
% of Operating Profit
Other Income/Expense, Net -$368.6K -$230.0K
YoY Change 60.26% -113.07%
Pretax Income -$19.70M -$13.10M
YoY Change 50.35% 129.9%
Income Tax $2.000K $2.000K
% Of Pretax Income
Net Earnings -$19.70M -$13.11M
YoY Change 50.34% 129.94%
Net Earnings / Revenue
Basic Earnings Per Share -$0.09 -$0.09
Diluted Earnings Per Share -$0.09 -$0.09
COMMON SHARES
Basic Shares Outstanding 219.1M 150.7M
Diluted Shares Outstanding 219.1M 150.7M

Balance Sheet

Concept 2022 Q1 2021 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $58.42M $37.17M
YoY Change 57.18% 699.35%
Cash & Equivalents $58.42M $37.17M
Short-Term Investments
Other Short-Term Assets $8.123M $6.620M
YoY Change 22.71% 37.06%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $66.55M $43.79M
YoY Change 51.97% 361.43%
LONG-TERM ASSETS
Property, Plant & Equipment $81.81K $250.0K
YoY Change -67.28% -92.04%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $824.0K $900.0K
YoY Change -8.45%
Other Assets $141.9K $1.070M
YoY Change -86.74% 98.15%
Total Long-Term Assets $1.139M $1.320M
YoY Change -13.72% -64.13%
TOTAL ASSETS
Total Short-Term Assets $66.55M $43.79M
Total Long-Term Assets $1.139M $1.320M
Total Assets $67.69M $45.11M
YoY Change 50.05% 242.52%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.160M $6.330M
YoY Change -34.28% 91.24%
Accrued Expenses $2.550M $4.500M
YoY Change -43.34% -41.1%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change -100.0%
Long-Term Debt Due $22.80M $11.21M
YoY Change 103.39% 202.16%
Total Short-Term Liabilities $31.41M $23.90M
YoY Change 31.43% 0.8%
LONG-TERM LIABILITIES
Long-Term Debt $10.33K $160.0K
YoY Change -93.54% -98.37%
Other Long-Term Liabilities $302.0K $400.0K
YoY Change -24.51% 166.67%
Total Long-Term Liabilities $312.3K $560.0K
YoY Change -44.23% -94.39%
TOTAL LIABILITIES
Total Short-Term Liabilities $31.41M $23.90M
Total Long-Term Liabilities $312.3K $560.0K
Total Liabilities $31.72M $24.46M
YoY Change 29.7% -27.4%
SHAREHOLDERS EQUITY
Retained Earnings -$377.1M
YoY Change
Common Stock $413.0M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $35.96M $20.65M
YoY Change
Total Liabilities & Shareholders Equity $67.69M $45.11M
YoY Change 50.05% 242.52%

Cashflow Statement

Concept 2022 Q1 2021 Q1
OPERATING ACTIVITIES
Net Income -$19.70M -$13.11M
YoY Change 50.34% 129.94%
Depreciation, Depletion And Amortization $40.91K $40.91K
YoY Change 0.0% -75.94%
Cash From Operating Activities -$14.33M -$11.75M
YoY Change 21.99% 65.73%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 2.608M 43.34M
YoY Change -93.98% 316.73%
NET CHANGE
Cash From Operating Activities -14.33M -11.75M
Cash From Investing Activities
Cash From Financing Activities 2.608M 43.34M
Net Change In Cash -11.73M 31.59M
YoY Change -137.12% 854.38%
FREE CASH FLOW
Cash From Operating Activities -$14.33M -$11.75M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
4159987
CY2021Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
2196349
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-37759
CY2021Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
26995
CY2022Q1 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
298033
CY2021Q3 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
522918
CY2022Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q1 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
CY2021Q3 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
CY2022Q1 us-gaap Preferred Stock Value
PreferredStockValue
CY2021Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2022Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2549876
CY2021Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1725721
CY2022Q1 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
1856629
CY2021Q3 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
1856629
CY2022Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
225792742
dei Entity Central Index Key
EntityCentralIndexKey
0001649989
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Amendment Flag
AmendmentFlag
false
CY2021Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
176461628
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-03-31
dei Entity Registrant Name
EntityRegistrantName
OUTLOOK THERAPEUTICS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
38-3982704
dei Entity Address Address Line1
EntityAddressAddressLine1
485 Route 1 South
dei Entity Address Address Line2
EntityAddressAddressLine2
Building F, Suite 320
dei Entity Address City Or Town
EntityAddressCityOrTown
Iselin
dei Entity Address State Or Province
EntityAddressStateOrProvince
NJ
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
08830
dei City Area Code
CityAreaCode
609
dei Local Phone Number
LocalPhoneNumber
619-3990
dei Security12b Title
Security12bTitle
Common Stock
dei Trading Symbol
TradingSymbol
OTLK
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
225942719
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
58424097
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
14477324
CY2022Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
8123275
CY2021Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
7030823
CY2022Q1 us-gaap Assets Current
AssetsCurrent
66547372
CY2021Q3 us-gaap Assets Current
AssetsCurrent
21508147
CY2022Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
81812
CY2021Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
163625
CY2022Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
91289
CY2021Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
111429
CY2022Q1 us-gaap Equity Method Investments
EquityMethodInvestments
823961
CY2021Q3 us-gaap Equity Method Investments
EquityMethodInvestments
853660
CY2022Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
141859
CY2021Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
174590
CY2022Q1 us-gaap Assets
Assets
67686293
CY2021Q3 us-gaap Assets
Assets
22811451
CY2022Q1 us-gaap Long Term Debt Fair Value
LongTermDebtFairValue
12557521
CY2022Q1 us-gaap Notes And Loans Payable Current
NotesAndLoansPayableCurrent
22781233
CY2021Q3 us-gaap Notes And Loans Payable Current
NotesAndLoansPayableCurrent
904200
CY2022Q1 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
18422
CY2021Q3 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
26464
CY2022Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
45171
CY2021Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
42854
CY2022Q1 us-gaap Liabilities Current
LiabilitiesCurrent
31411318
CY2021Q3 us-gaap Liabilities Current
LiabilitiesCurrent
6752217
CY2021Q3 us-gaap Long Term Notes And Loans
LongTermNotesAndLoans
10885854
CY2022Q1 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
10332
CY2021Q3 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
16018
CY2022Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
3929
CY2022Q1 us-gaap Liabilities
Liabilities
31723612
CY2021Q3 us-gaap Liabilities
Liabilities
18204002
CY2022Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2021Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2022Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
7300000
CY2021Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
7300000
CY2022Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2021Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2022Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
325000000
CY2021Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
325000000
CY2022Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
225792742
CY2021Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
176461628
CY2022Q1 us-gaap Common Stock Value
CommonStockValue
2257927
CY2021Q3 us-gaap Common Stock Value
CommonStockValue
1764616
CY2022Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
410755286
CY2021Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
345726087
CY2022Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-377050532
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-342883254
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
35962681
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
4607449
CY2022Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
67686293
CY2021Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
22811451
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
12219666
CY2021Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8529393
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
22092142
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
20477974
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6689914
CY2021Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4095891
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9967119
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6338245
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-18909580
CY2021Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-12625284
us-gaap Operating Income Loss
OperatingIncomeLoss
-32059261
us-gaap Operating Income Loss
OperatingIncomeLoss
-26816219
CY2022Q1 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-6044
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-29699
CY2022Q1 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-418327
CY2021Q1 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-250409
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-1025402
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.17
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.20
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-769861
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-410072
CY2022Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
-343585
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
-505940
CY2022Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
25013
CY2021Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
228828
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-224885
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
334144
CY2022Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-19702549
CY2021Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-13104521
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-34165278
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-27560435
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2000
CY2021Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2000
CY2022Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-19704549
CY2021Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-13106521
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-34167278
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-27562435
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.09
CY2021Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.09
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
219067900
CY2021Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
150730191
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
203443077
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
136080637
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
4607449
CY2021Q4 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
17750
CY2021Q4 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
57456903
CY2021Q4 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
1204048
CY2021Q4 us-gaap Net Income Loss
NetIncomeLoss
-14462729
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
48823421
CY2022Q1 otlk Stock Issue During Period Value In Connection With Exercise Of Warrants
StockIssueDuringPeriodValueInConnectionWithExerciseOfWarrants
188100
CY2022Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
2892914
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
3762795
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-19704549
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
35962681
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
2826291
CY2020Q4 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
1154641
CY2020Q4 us-gaap Net Income Loss
NetIncomeLoss
-14455914
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-10474982
CY2021Q1 otlk Stock Issue During Period Value In Connection With Exercise Of Warrants
StockIssueDuringPeriodValueInConnectionWithExerciseOfWarrants
3585809
CY2021Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
39517119
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
1129747
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-13106521
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
20651172
us-gaap Net Income Loss
NetIncomeLoss
-34167278
us-gaap Net Income Loss
NetIncomeLoss
-27562435
us-gaap Depreciation And Amortization
DepreciationAndAmortization
101953
us-gaap Depreciation And Amortization
DepreciationAndAmortization
163283
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-1025402
us-gaap Paid In Kind Interest
PaidInKindInterest
763104
us-gaap Paid In Kind Interest
PaidInKindInterest
392028
us-gaap Share Based Compensation
ShareBasedCompensation
4966843
us-gaap Share Based Compensation
ShareBasedCompensation
2284388
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
-505940
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-224885
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
334144
us-gaap Gain Loss On Termination Of Lease
GainLossOnTerminationOfLease
552340
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-29699
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1092452
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1323108
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-137579
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-20749
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-91721
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1963638
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
3685278
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
824155
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-2537903
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-25324630
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-25070807
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
60382548
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
39779507
us-gaap Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
10000000
us-gaap Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
10000000
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
8032
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
188100
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
3585809
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
17750
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
13728
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
16533
us-gaap Repayments Of Debt
RepaymentsOfDebt
703267
us-gaap Repayments Of Debt
RepaymentsOfDebt
3637076
us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
600000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
69271403
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
49703675
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
43946773
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
24632868
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
14477324
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
12535986
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
58424097
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
37168854
us-gaap Interest Paid Net
InterestPaidNet
22017
us-gaap Interest Paid Net
InterestPaidNet
10490
otlk Deferred Offering Costs And Common Stock Issuance Costs In Accounts Payable And Accrued Expenses
DeferredOfferingCostsAndCommonStockIssuanceCostsInAccountsPayableAndAccruedExpenses
262388
otlk Amortization Of Deferred Offering Cost
AmortizationOfDeferredOfferingCost
32731
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
203443077
us-gaap Nature Of Operations
NatureOfOperations
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">1.     Organization and Description of Business</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Outlook Therapeutics, Inc. (“Outlook” or the “Company”) was incorporated in New Jersey on January 5, 2010, started operations in July 2011, reincorporated in Delaware by merging with and into a Delaware corporation in October 2015 and changed its name to “Outlook Therapeutics, Inc.” in November 2018. The Company is a pre-commercial biopharmaceutical company focused on developing and commercializing ONS-5010, an ophthalmic formulation of bevacizumab for use in retinal indications. The Company is based in Iselin, New Jersey.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company has been actively monitoring the ongoing COVID-19 pandemic and its impact globally. Given the Company’s current infrastructure needs and current strategy, the Company was able to transition to remote working with limited impact on productivity, as shelter-in-place and similar government orders were imposed. All development activities are currently active in support of the Company’s Biologics License Application (“BLA”) registration program for ONS-5010 for wet age-related macular degeneration (“wet AMD”).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The full extent to which the COVID-19 pandemic will directly or indirectly impact the Company’s business, results of operations and financial condition will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain it or treat COVID-19. Management believes the financial results for the three and six months ended March 31, 2022 were not significantly impacted by COVID-19.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p>
CY2022Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-377050532
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Use of estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The preparation of the unaudited interim consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Due to the uncertainty of factors surrounding the estimates or judgments used in the preparation of the unaudited interim consolidated financial statements, including as a result of the ongoing COVID-19 pandemic, actual results may materially vary from these estimates. Estimates and assumptions are periodically reviewed, and the effects of revisions are reflected in the unaudited interim consolidated financial statements in the period they are determined to be necessary.</p>
CY2022Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-19704549
CY2021Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-13106521
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-34167278
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-27562435
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
219067900
CY2021Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
150730191
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
136080637
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.09
CY2021Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.09
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.17
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.20
CY2022Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1067351
CY2021Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1067351
CY2022Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
985539
CY2021Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
903726
CY2022Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
81812
CY2021Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
163625
CY2021Q1 us-gaap Depreciation
Depreciation
40906
CY2022Q1 us-gaap Depreciation
Depreciation
40906
us-gaap Depreciation
Depreciation
81813
us-gaap Depreciation
Depreciation
81812
CY2022Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
774484
CY2021Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
753808
CY2022Q1 otlk Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
1151115
CY2021Q3 otlk Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
808780
CY2022Q1 us-gaap Interest Payable Current
InterestPayableCurrent
89
CY2021Q3 us-gaap Interest Payable Current
InterestPayableCurrent
12909
CY2022Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
206079
CY2022Q1 otlk Accrued Commercial Consulting Services Current
AccruedCommercialConsultingServicesCurrent
216729
CY2022Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
201380
CY2021Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
150224
CY2022Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2549876
CY2021Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1725721
CY2022Q1 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
23349055
CY2021Q3 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
11842345
CY2022Q1 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
567822
CY2021Q3 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
52291
CY2022Q1 us-gaap Notes And Loans Payable
NotesAndLoansPayable
22781233
CY2021Q3 us-gaap Notes And Loans Payable
NotesAndLoansPayable
11790054
CY2022Q1 us-gaap Notes And Loans Payable Current
NotesAndLoansPayableCurrent
22781233
CY2021Q3 us-gaap Notes And Loans Payable Current
NotesAndLoansPayableCurrent
904200
CY2021Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
69849
CY2022Q1 us-gaap Finance Lease Liability
FinanceLeaseLiability
28754
CY2021Q3 us-gaap Finance Lease Liability
FinanceLeaseLiability
42482
CY2021Q3 us-gaap Long Term Notes And Loans
LongTermNotesAndLoans
10885854
CY2020Q3 us-gaap Loss Contingency Damages Sought Value
LossContingencyDamagesSoughtValue
3000000
CY2021Q2 us-gaap Litigation Settlement Amount Awarded To Other Party
LitigationSettlementAmountAwardedToOtherParty
625000
CY2022Q2 us-gaap Litigation Settlement Amount Awarded To Other Party
LitigationSettlementAmountAwardedToOtherParty
750000
CY2022Q1 us-gaap Litigation Reserve Current
LitigationReserveCurrent
0
CY2022Q1 us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
849
CY2021Q1 us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
1005
us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
1823
us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
2787
CY2022Q1 otlk Finance Lease Cost
FinanceLeaseCost
849
CY2021Q1 otlk Finance Lease Cost
FinanceLeaseCost
1005
otlk Finance Lease Cost
FinanceLeaseCost
1823
otlk Finance Lease Cost
FinanceLeaseCost
2787
CY2022Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
11217
CY2021Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
43625
us-gaap Operating Lease Cost
OperatingLeaseCost
22433
us-gaap Operating Lease Cost
OperatingLeaseCost
87250
CY2022Q1 us-gaap Lease Cost
LeaseCost
12066
CY2021Q1 us-gaap Lease Cost
LeaseCost
44630
us-gaap Lease Cost
LeaseCost
24256
us-gaap Lease Cost
LeaseCost
90037
CY2022Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
91289
CY2021Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
111429
CY2022Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
49100
CY2022Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y1M6D
CY2021Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y7M6D
CY2022Q1 us-gaap Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
P1Y4M24D
CY2021Q3 us-gaap Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
P1Y8M12D
CY2022Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.075
CY2021Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.075
CY2022Q1 us-gaap Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
0.107
CY2021Q3 us-gaap Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
0.095
us-gaap Finance Lease Interest Payment On Liability
FinanceLeaseInterestPaymentOnLiability
1823
us-gaap Finance Lease Interest Payment On Liability
FinanceLeaseInterestPaymentOnLiability
2787
us-gaap Operating Lease Payments
OperatingLeasePayments
23043
us-gaap Operating Lease Payments
OperatingLeasePayments
97500
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
13728
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
16533
CY2022Q1 us-gaap Finance Lease Liability Undiscounted Excess Amount
FinanceLeaseLiabilityUndiscountedExcessAmount
2833
CY2022Q1 us-gaap Finance Lease Liability Payments Due
FinanceLeaseLiabilityPaymentsDue
31587
CY2022Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
2183
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
23608
CY2022Q1 us-gaap Finance Lease Liability Payments Remainder Of Fiscal Year
FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear
14055
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
27675
CY2022Q1 us-gaap Finance Lease Liability Payments Due Next Twelve Months
FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
13149
CY2022Q1 us-gaap Finance Lease Liability Payments Due Year Two
FinanceLeaseLiabilityPaymentsDueYearTwo
4383
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
51283
CY2022Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
49100
CY2022Q1 us-gaap Finance Lease Liability
FinanceLeaseLiability
28754
CY2022Q1 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
6812794
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3762795
CY2021Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1129747
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4966843
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2284388

Files In Submission

Name View Source Status
0001558370-22-008780-index-headers.html Edgar Link pending
0001558370-22-008780-index.html Edgar Link pending
0001558370-22-008780.txt Edgar Link pending
0001558370-22-008780-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
otlk-20220331.xsd Edgar Link pending
otlk-20220331x10q.htm Edgar Link pending
otlk-20220331x10q_htm.xml Edgar Link completed
otlk-20220331xex31d1.htm Edgar Link pending
otlk-20220331xex31d2.htm Edgar Link pending
otlk-20220331xex32d1.htm Edgar Link pending
otlk-20220331_cal.xml Edgar Link unprocessable
otlk-20220331_def.xml Edgar Link unprocessable
otlk-20220331_lab.xml Edgar Link unprocessable
otlk-20220331_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending